Nathan T. Connell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathan T. Connell has a total of 406 co-authors. Here are the top co-authors by number of shared publications:
- Paula James
Department of Medicine, Queen's University, Kingston, Canada
9 shared publications - Mohamad A. Kalot
Department of Internal Medicine, State University of New York at Buffalo, Buffalo, NY
8 shared publications Nedaa Husainat
Department of Internal Medicine, St. Mary's Hospital, St. Louis, MO
7 shared publications- Reem A. Mustafa
University of Kansas Medical Center, Kansas City, Kansas, United States
7 shared publications - Romina Brignardello-Petersen
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada
7 shared publications - Jean Marie Connors
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
6 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Thrombosis Update
- Vol. 25
A retrospective evaluation of clotting factor concentrate usage for the periprocedural management of patients with hemophilia A before and after the introduction of emicizumab
- 4 November 2026
- Published by Elsevier in Thrombosis Update
- Vol. 25
Open AccessA retrospective evaluation of clotting factor concentrate usage for the periprocedural management of patients with hemophilia A before and after the introduction of emicizumab
- 29 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7269-7270
Hematologic care for transgender and gender-diverse people
- 29 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7269-7270
Hematologic care for transgender and gender-diverse people
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7230-7242
The hematology workforce in the United States: past, present, and strategies for the future
From 2017 to 2021, the American Society of Hematology (ASH) conducted the largest study to date of the hematology workforce in the United States. The study highlighted a deficit in the classical hematology (CH) workforce. Despite the very high CH clinical volumes encountered by practicing hematologists and medical oncologists, <5% of all hematology and medical oncology fellows reported having a career focus in CH. The reason underlying this deficit was a lack of mentorship in CH compared with malignant hematology and solid tumor oncology. In this viewpoint article, we discuss factors shaping the US hematology workforce and how decades of inadequate investment in mentorship, research, and subspecialty training have contributed to low interest in CH among trainees. We present an overview of ASH’s many initiatives to grow the hematology clinical and research workforce in the United States and globally for the future of the field.
- 28 October 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (21) , 7230-7242
The hematology workforce in the United States: past, present, and strategies for the future
From 2017 to 2021, the American Society of Hematology (ASH) conducted the largest study to date of the hematology workforce in the United States. The study highlighted a deficit in the classical hematology (CH) workforce. Despite the very high CH clinical volumes encountered by practicing hematologists and medical oncologists, <5% of all hematology and medical oncology fellows reported having a career focus in CH. The reason underlying this deficit was a lack of mentorship in CH compared with malignant hematology and solid tumor oncology. In this viewpoint article, we discuss factors shaping the US hematology workforce and how decades of inadequate investment in mentorship, research, and subspecialty training have contributed to low interest in CH among trainees. We present an overview of ASH’s many initiatives to grow the hematology clinical and research workforce in the United States and globally for the future of the field.
- 30 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6719-6728
Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States
Von Willebrand factor (VWF) concentrate prophylaxis is recommended for patients with severe von Willebrand disease (VWD) or VWD with frequent bleeding symptoms but remains underused due, in part, to the high direct cost associated with regular concentrate administration. Robust cost-effectiveness data for VWF prophylaxis are limited, with most analyses relying on literature-based assumptions rather than prospective clinical data. A trial-based cost-effectiveness analysis was developed to estimate the long-term economic impact of plasma-derived VWF/factor VIII (Wilate) prophylaxis vs on-demand therapy in patients with type 3 VWD in the United States, from both payer and societal perspectives. Clinical inputs were derived directly from phase 3 clinical studies, whereas health care costs were obtained from published sources. Productivity losses during bleeding events were incorporated into the societal analysis. Subgroup analyses were performed for adults and adult women with type 3 VWD, and evaluations were conducted for both 1-year and lifetime horizons. The payer analysis highlighted potential cost savings with Wilate prophylaxis across all groups, with estimated annual savings of $10 898 per individual in the overall type 3 VWD cohort, $53 264 among adults, and $125 712 among women. Savings were higher in the societal perspective, with the largest benefit observed in women ($148 555 per individual annually). The primary cost drivers were bleeding rates and treatment costs during on-demand therapy. In addition to its established clinical efficacy, these findings demonstrate a potential substantial economic advantage of Wilate prophylaxis and support broader adoption of VWF-based prophylaxis for individuals with type 3 VWD in the United States.
- 30 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6719-6728
Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States
Von Willebrand factor (VWF) concentrate prophylaxis is recommended for patients with severe von Willebrand disease (VWD) or VWD with frequent bleeding symptoms but remains underused due, in part, to the high direct cost associated with regular concentrate administration. Robust cost-effectiveness data for VWF prophylaxis are limited, with most analyses relying on literature-based assumptions rather than prospective clinical data. A trial-based cost-effectiveness analysis was developed to estimate the long-term economic impact of plasma-derived VWF/factor VIII (Wilate) prophylaxis vs on-demand therapy in patients with type 3 VWD in the United States, from both payer and societal perspectives. Clinical inputs were derived directly from phase 3 clinical studies, whereas health care costs were obtained from published sources. Productivity losses during bleeding events were incorporated into the societal analysis. Subgroup analyses were performed for adults and adult women with type 3 VWD, and evaluations were conducted for both 1-year and lifetime horizons. The payer analysis highlighted potential cost savings with Wilate prophylaxis across all groups, with estimated annual savings of $10 898 per individual in the overall type 3 VWD cohort, $53 264 among adults, and $125 712 among women. Savings were higher in the societal perspective, with the largest benefit observed in women ($148 555 per individual annually). The primary cost drivers were bleeding rates and treatment costs during on-demand therapy. In addition to its established clinical efficacy, these findings demonstrate a potential substantial economic advantage of Wilate prophylaxis and support broader adoption of VWF-based prophylaxis for individuals with type 3 VWD in the United States.
- Open Access
- 5 April 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?
A deficiency and/or dysfunction of von Willebrand factor (VWF) or factor VIII (FVIII) results in the bleeding disorders of von Willebrand disease (VWD) and hemophilia A (HA), respectively. Whereas HA impacts coagulation, VWD primarily impairs hemostasis through defective platelet adhesion and aggregation. In addition, because VWF protects FVIII from proteolytic degradation, a deficiency in VWF can also reduce FVIII levels and affect coagulation. While regular prophylaxis to restore FVIII activity is the standard of care for severe HA, its use to correct the dual VWF/FVIII defect in severe VWD is less well established. Current treatment guidelines suggest the use of long-term prophylaxis rather than no prophylaxis in persons with VWD with a history of severe and frequent bleeds. In this narrative review, we discuss the barriers to the broader adoption of prophylaxis in persons with severe VWD and results of recent clinical studies that provide further evidence to support its use. A growing body of evidence suggests that prophylaxis should be established as the standard care for individuals with severe VWD and recurrent bleeding.
- 5 April 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessProphylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?
A deficiency and/or dysfunction of von Willebrand factor (VWF) or factor VIII (FVIII) results in the bleeding disorders of von Willebrand disease (VWD) and hemophilia A (HA), respectively. Whereas HA impacts coagulation, VWD primarily impairs hemostasis through defective platelet adhesion and aggregation. In addition, because VWF protects FVIII from proteolytic degradation, a deficiency in VWF can also reduce FVIII levels and affect coagulation. While regular prophylaxis to restore FVIII activity is the standard of care for severe HA, its use to correct the dual VWF/FVIII defect in severe VWD is less well established. Current treatment guidelines suggest the use of long-term prophylaxis rather than no prophylaxis in persons with VWD with a history of severe and frequent bleeds. In this narrative review, we discuss the barriers to the broader adoption of prophylaxis in persons with severe VWD and results of recent clinical studies that provide further evidence to support its use. A growing body of evidence suggests that prophylaxis should be established as the standard care for individuals with severe VWD and recurrent bleeding.
- Open Access
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 794-801
Treatment of von Willebrand disease
Treatment for von Willebrand disease (VWD), the most common inherited bleeding disorder, has advanced considerably since its initial description by Erik von Willebrand who first described a family in the Åland Islands with severe bleeding. Infusion of von Willebrand factor (VWF)–containing concentrates continues to serve as the foundation of management, in addition to desmopressin, hormonal therapies, and antifibrinolytic agents such as tranexamic acid. Recent advancements in VWD management are underscored by the publication of evidence-based international guidelines addressing critical aspects such as VWF prophylaxis, the use of anticoagulants and antiplatelet agents for cardiovascular disease, and comprehensive management during surgical as well as obstetric and gynecologic scenarios. This review provides an overview of modern treatment strategies, discusses management in special populations, and explores emerging therapies and future directions for improving VWD care.
- 2 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (3) , 794-801
Open AccessTreatment of von Willebrand disease
Treatment for von Willebrand disease (VWD), the most common inherited bleeding disorder, has advanced considerably since its initial description by Erik von Willebrand who first described a family in the Åland Islands with severe bleeding. Infusion of von Willebrand factor (VWF)–containing concentrates continues to serve as the foundation of management, in addition to desmopressin, hormonal therapies, and antifibrinolytic agents such as tranexamic acid. Recent advancements in VWD management are underscored by the publication of evidence-based international guidelines addressing critical aspects such as VWF prophylaxis, the use of anticoagulants and antiplatelet agents for cardiovascular disease, and comprehensive management during surgical as well as obstetric and gynecologic scenarios. This review provides an overview of modern treatment strategies, discusses management in special populations, and explores emerging therapies and future directions for improving VWD care.
- Open Access
- 2 September 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 815-822
Bridging the Evidence Gap in von Willebrand Disease: A Call to Action for Equitable, Evidence‐Based Care
- 2 September 2025
- Published by Wiley in Haemophilia
- Vol. 31 (5) , 815-822
Open AccessBridging the Evidence Gap in von Willebrand Disease: A Call to Action for Equitable, Evidence‐Based Care
- Open Access
- 1 August 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center
Background: Eptacog alfa and eptacog beta are recombinant factor VIIa (rFVIIa) agents approved for use in hemophilia A or B with inhibitors. Our institution converted from eptacog alfa to eptacog beta as the preferred rFVIIa product. The objective of this medication use evaluation was to review the utilization of both agents and cost savings associated with the conversion. Methods: We performed a retrospective chart review for all eptacog alfa and beta administrations from October 2023 through September 2024. We evaluated product selection and dosing as well as the occurrence of thrombosis, new bleeding events, or existing bleeding that required therapy escalation. Cost savings were estimated using wholesale acquisition costs. Results: There were 17 patients that required 27 admissions for rFVIIa (eptacog alfa: 3, 11.1% and eptacog beta: 21, 77.8%). Three administrations (11.1%) utilized both agents. Indications included bleeding in hemophilia patients (12, 44.4%), followed by peri-procedural management (9, 33.3%), cardiac surgery (3, 11.1%), and anticoagulation reversal for life-threatening bleeding (3, 11.1%). There were 21 administrations in which eptacog beta was exclusively used (bleeding in hemophilia A (9, 33.3%), peri-procedural management (7, 25.9%), cardiac surgery (2, 7.4%), and anticoagulation reversal (3, 11.1%)). There were no thrombotic events. There were 5 patients (18.5%) who required rFVIIa dose escalation and two (7.4%) who required re-initiation of rFVIIa. Cost avoidance was estimated at $554,400 over a 12-month period. Conclusion: We treated a small cohort of patients with eptacog beta without adverse outcomes. Other hospitals might evaluate their rFVIIa use and consider opportunities for substitution.
- 1 August 2025
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Open AccessReal World Experience with use of Coagulation Factor VIIa at an Academic Medical Center
Background: Eptacog alfa and eptacog beta are recombinant factor VIIa (rFVIIa) agents approved for use in hemophilia A or B with inhibitors. Our institution converted from eptacog alfa to eptacog beta as the preferred rFVIIa product. The objective of this medication use evaluation was to review the utilization of both agents and cost savings associated with the conversion. Methods: We performed a retrospective chart review for all eptacog alfa and beta administrations from October 2023 through September 2024. We evaluated product selection and dosing as well as the occurrence of thrombosis, new bleeding events, or existing bleeding that required therapy escalation. Cost savings were estimated using wholesale acquisition costs. Results: There were 17 patients that required 27 admissions for rFVIIa (eptacog alfa: 3, 11.1% and eptacog beta: 21, 77.8%). Three administrations (11.1%) utilized both agents. Indications included bleeding in hemophilia patients (12, 44.4%), followed by peri-procedural management (9, 33.3%), cardiac surgery (3, 11.1%), and anticoagulation reversal for life-threatening bleeding (3, 11.1%). There were 21 administrations in which eptacog beta was exclusively used (bleeding in hemophilia A (9, 33.3%), peri-procedural management (7, 25.9%), cardiac surgery (2, 7.4%), and anticoagulation reversal (3, 11.1%)). There were no thrombotic events. There were 5 patients (18.5%) who required rFVIIa dose escalation and two (7.4%) who required re-initiation of rFVIIa. Cost avoidance was estimated at $554,400 over a 12-month period. Conclusion: We treated a small cohort of patients with eptacog beta without adverse outcomes. Other hospitals might evaluate their rFVIIa use and consider opportunities for substitution.
- Open Access
- 11 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3553-3555
2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease
The American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF; now National Bleeding Disorders Foundation), and World Federation of Hemophilia (WFH) 2021 guidelines on the diagnosis and management of von Willebrand disease (VWD) included 11 recommendations on the diagnosis of VWD and 12 recommendations on the management of VWD, the most common inherited bleeding disorder. We describe the results of a review of the 2021 guidelines by the clinical co-chairs of the guideline panels requested by ASH to inform decision-making about the need for and timing of a guideline revision. An updated MEDLINE and Embase search applied the same terms as the ASH ISTH NHF WFH 2021 guidelines limited to studies from 2020 to 30 July 2024 (diagnosis) or 24 July 2024 (management). For the diagnosis of VWD, 432 studies were identified and underwent title and abstract review, with 17 undergoing full text review, and for the management of VWD, 288 studies were identified and underwent title and abstract review, with 37 undergoing full text review, to determine whether the data would change the strength or directionality of the existing recommendation or merit development of a new recommendation. Based on this review, the clinical co-chairs noted that none of the reviewed studies would change the direction or strength of the existing guideline recommendations. There will be continued monitoring of the ASH ISTH NHF WFH 2021 guidelines on the diagnosis and management of VWD to evaluate whether there is sufficient new evidence to warrant additional revisions.
- 11 July 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (14) , 3553-3555
Open Access2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease
The American Society of Hematology (ASH), International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF; now National Bleeding Disorders Foundation), and World Federation of Hemophilia (WFH) 2021 guidelines on the diagnosis and management of von Willebrand disease (VWD) included 11 recommendations on the diagnosis of VWD and 12 recommendations on the management of VWD, the most common inherited bleeding disorder. We describe the results of a review of the 2021 guidelines by the clinical co-chairs of the guideline panels requested by ASH to inform decision-making about the need for and timing of a guideline revision. An updated MEDLINE and Embase search applied the same terms as the ASH ISTH NHF WFH 2021 guidelines limited to studies from 2020 to 30 July 2024 (diagnosis) or 24 July 2024 (management). For the diagnosis of VWD, 432 studies were identified and underwent title and abstract review, with 17 undergoing full text review, and for the management of VWD, 288 studies were identified and underwent title and abstract review, with 37 undergoing full text review, to determine whether the data would change the strength or directionality of the existing recommendation or merit development of a new recommendation. Based on this review, the clinical co-chairs noted that none of the reviewed studies would change the direction or strength of the existing guideline recommendations. There will be continued monitoring of the ASH ISTH NHF WFH 2021 guidelines on the diagnosis and management of VWD to evaluate whether there is sufficient new evidence to warrant additional revisions.
- Open Access
- 9 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (2) , 151-153
STOP & GO: discontinuing TPO-RA in chronic ITP
In this issue of Blood, Cottu and colleagues present data from the STOPAGO study demonstrating that nearly half of the patients with chronic ITP who achiev In this issue of Blood, Cottu and colleagues present data from the STOPAGO study demonstrating that nearly half of the patients with chronic ITP who achiev
- 9 January 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (2) , 151-153
Open AccessSTOP & GO: discontinuing TPO-RA in chronic ITP
In this issue of Blood, Cottu and colleagues present data from the STOPAGO study demonstrating that nearly half of the patients with chronic ITP who achiev In this issue of Blood, Cottu and colleagues present data from the STOPAGO study demonstrating that nearly half of the patients with chronic ITP who achiev